Last reviewed · How we verify
NCT04642547
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
NA trial testing Lenvatinib and Gefitinib in Hepatocellular Carcinoma in 30 participants. Completed in 31 March 2023.
31 March 2023
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 2 December 2020 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Lenvatinib and Gefitinib — full drug profile →
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
- Molecular Targeted Therapy — all drugs for Molecular Targeted Therapy →
Sponsor
RenJi Hospital
Who can join
Adults 18 to 75, any sex, with Hepatocellular Carcinoma or Molecular Targeted Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This study will help find out if lenvatinib and gefitinib is a safe and useful combination for treating patients with lenvatinib resistant hepatocellular carcinoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
EGFR activation limits the response of liver cancer to lenvatinib.
Jin H, Shi Y, Lv Y, Yuan S, et al · · 2021 · cited 369× · PMID 34290403 · DOI 10.1038/s41586-021-03741-7 -
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Wang SW, Gao C, Zheng YM, Yi L, et al · · 2022 · cited 305× · PMID 35189910 · DOI 10.1186/s12943-022-01518-8 -
Hepatocellular carcinoma: signaling pathways and therapeutic advances.
Zheng J, Wang S, Xia L, Sun Z, et al · · 2025 · cited 142× · PMID 39915447 · DOI 10.1038/s41392-024-02075-w -
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy.
Luo X, He X, Zhang X, Zhao X, et al · · 2024 · cited 64× · PMID 38318160 · DOI 10.1002/mco2.474 -
Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.
Zhou Y, Wang S, Wu W, Ling J, et al · · 2023 · cited 17× · PMID 36502574 · DOI 10.1016/j.ebiom.2022.104397 -
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow.
Becht R, Kiełbowski K, Wasilewicz MP. · · 2024 · cited 15× · PMID 38338736 · DOI 10.3390/ijms25031456 -
Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Tao M, Han J, Shi J, Liao H, et al · · 2023 · cited 14× · PMID 37457652 · DOI 10.2147/jhc.s411806 -
Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.
Shi Y, Cui D, Xia L, Shi D, et al · · 2024 · cited 13× · PMID 39653700 · DOI 10.1038/s41392-024-02085-8
Verify or expand the search:
- PubMed search for NCT04642547
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04642547 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04642547.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing